Evidence map›Paper›PMID 38746435›Full record

ArticleResearch square2024

Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.

Alexander Ishov, Sadia Sarwar, Viacheslav Morozov, Mallory Newcomb, Olga Guryanova

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Alexander IshovUniversity of Florida College of Medicine.ORCID 0000-0002-8823-8640
Sadia SarwarUniversity of Florida College of Medicine.
Viacheslav Morozov
Mallory NewcombUniversity of Florida College of Medicine.
Olga GuryanovaUniversity of Florida College of Medicine.ORCID 0000-0002-6514-8466

Funding

The Role of H3.3 histone variant in the pathogenesis of oral Kaposi's SarcomaR01DE026707 · NIDCR · UNIVERSITY OF FLORIDA · PI RENNE, ROLF F · 2018 to 2022
$1.8M
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesisR01DK121831 · NIDDK · UNIVERSITY OF FLORIDA · PI GURYANOVA, OLGA A · 2019 to 2023
$1.7M
Functions of histone variants in castration-resistance prostate cancerR21CA198820 · NCI · UNIVERSITY OF FLORIDA · PI ISHOV, ALEXANDER M · 2016 to 2017
$359k
NCI NIH HHS R21 CA198820NIDCR NIH HHS R01 DE026707NIDDK NIH HHS R01 DK121831
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. PCa that relapses after hormonal therapies, referred to as castration resistant PCa (CRPC), often presents with metastases (mCRPC) that are the major cause of mortality. The few available therapies for mCRPC patients include taxanes docetaxel (DTX) and cabazitaxel (CBZ). However, development of resistance limits their clinical use. Mechanistically, resistance arises through upregulation of multidrug resistance (MDR) proteins such as MDR1/ABCB1, making ABCB1 an attractive therapeutic target. Yet, ABCB1 inhibitors failed to be clinically useful due to low specificity and toxicity issues. To study taxanes resistance, we produced CBZ resistant C4-2B cells (RC4-2B) and documented resistance to both CBZ and DTX in cell culture and in 3D prostaspheres settings. RNAseq identified increased expression of

Indexed as

ABCB1chemotherapyDNA damage agentsmultidrug resistanceprostate cancertaxanes

Identifiers

PMID38746435
PMCPMC11092792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.